SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is generating significant buzz as a nostalgic parody project, with the community actively debating whether its long-standing history dating back to 2011 gives it more staying power than typical meme coins. Advocates are rallying behind the project's relaunch by its original creator, viewing the coin as a satirical mirror to Bitcoin that is positioned for future growth despite skepticism over its comedic nature.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility and significant social media attention as traders debate whether the asset is in the midst of a sustainable growth phase or a high-risk pump-and-dump cycle. While bulls point to the token's real-world use case in the decentralized event and music sector and recent institutional partnership rumors, skeptics remain wary of potential sell-offs and significant token supply releases.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic is trending as investors weigh persistent supply-chain riskscompounded by Middle East tensions and shifting trade policyagainst the company's valuation as a major North American real-asset producer. The community remains heavily divided between those viewing the stock as a deeply undervalued play on critical agricultural inputs and food security, and skeptics wary of margin pressures, geopolitical headlines, and ongoing analyst downgrades.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is experiencing intense selling pressure and a severe stock decline as investors aggressively rotate out of the software sector, fueled by fears that AI-driven tools will commoditize enterprise workflows. While a segment of the community remains focused on the stock's discounted valuation and the sticky nature of Jira and Confluence, bears and institutional de-risking continue to dominate the narrative, pushing the symbol toward fresh 52-week lows.

GitLab, Inc. engages in the intelligent development, security, and operations (DevSecOps) platform for software innovation. It enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab ($GTLB) is trending as investors weigh potential buyout interest alongside concerns that AI-driven coding tools may disrupt its long-term growth and market share. Community members are actively debating the stock's valuation as a recovery play, while simultaneously tracking high-volume trading activity and rumors of strategic acquisition interest.

Maulcoin

Maulcoin is surging in community sentiment following the restoration of its ticker symbol and increased efforts toward exchange verification. Investors are actively discussing the project's organic growth and potential for future momentum as they transition from a community-driven grassroots phase toward more formalized market tracking.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is currently capturing significant investor attention as gold prices hit historic highs, fueling speculation about long-term valuation shifts and potential production expansions at its Reko Diq and Four Mile projects. Community discussion is heavily focused on whether the company's recent operational updates and strategic focus on value maximization through a proposed North American assets IPO will successfully unlock latent value amid the ongoing gold bull cycle.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors debate the impact of the pending CLARITY Act and Ripple's potential role in global banking infrastructure. The community remains deeply divided, with some users accumulating on expectations of regulatory breakthroughs while others express frustration over stagnant price action and recurring escrow releases.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility driven by a rare public endorsement from President Trump, which has sparked intense debate between investors viewing it as a critical defense infrastructure play and those following bearish narratives from figures like Michael Burry. Community discourse is sharply divided between tactical traders attempting to capitalize on the political headlines and long-term believers defending the company's entrenchment within government and military AI operations despite ongoing valuation concerns.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility and significant momentum, driven by a new $71 million follow-on order for 800G transceivers that reinforces the company's deepening pipeline with major hyperscalers. While bulls are focused on the company's vertical integration and the critical role of photonics in the AI data center buildout, the community is sharply divided by a high-profile short thesis citing valuation concerns, margin pressure, and customer concentration risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Revance Therapeutics surged more than 16% on Monday morning, reaching over a month’s high, leading to a jump in retail chatter on Stocktwits.The surge followed a proposal from privately held Swiss medical aesthetics company Teoxane to acquire the anti-wrinkle injection maker for $3.60 per share in cash.&nbsp;The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rvnc-stock-tanks-after-crown-labs-halves-takeover-price/cJabclHRig">announced</a> last month.Revance has yet to comment publicly on the proposal, but the news triggered a spike in message volume on Stocktwits, where retail sentiment remained cautious with a ‘neutral’ score.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RVNC_sentiment_and_message_volume_Jan_6_1855360b7a.png" alt="RVNC sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>RVNC sentiment and message volume Jan 6 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Last year, Crown agreed to purchase Revance for $6.66 per share, but the deal faced delays due to a dispute with Teoxane over Revance’s breach of a 2020 distribution agreement.&nbsp;The agreement had made Revance the exclusive commercialization partner for Teoxane’s dermal fillers. After resolving the dispute, Revance and Crown amended their deal, slashing the takeover price by more than half, reducing it to approximately $323 million.Teoxane currently holds 6.2% of Revance’s outstanding shares.&nbsp;Despite the uptick in shares following the Teoxane proposal, Revance's stock has struggled recently, plunging around 65% last year.Last year, Revance Therapeutics announced the commercial launch of DAXXIFY for injection for the treatment of cervical dystonia, marking its entry into the expanding U.S. therapeutics neurotoxin market, which could play a role in reshaping its future prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs

The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.

Equity

Shares of Revance Therapeutics Inc. plummeted over 20% to a four-month low Monday after private skincare firm Crown Laboratories drastically reduced its takeover offer.Crown will now acquire Revance in an all-cash deal valued at $3.10 per share, down from the initial August agreement of $6.66 per share.&nbsp;The revised deal, worth about $325 million in total equity, marks an 18.9% discount to Revance’s Dec. 6 closing price.&nbsp;The acquisition will make Revance a private company, with the deal expected to close in the first quarter of 2025.The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.&nbsp;Both companies acknowledged that these violations could significantly impact Revance’s profitability and cash flows, prompting the adjustment.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_09_at_11_31_10_AM_0b2b5cca48.png" alt="Screenshot 2024-12-09 at 11.31.10 AM.png" width="1314" height="320"><figcaption>RVNC sentiment and message volume on Dec. 9 as of 11:30 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned sharply bearish, accompanied by ‘extremely high’ message volume as investors expressed frustration.&nbsp;Posts highlighted disappointment with the slashed valuation and uncertainty about Revance’s future.<stembedurl>https://stocktwits.com/Hedgieguy75/message/595701639</stembedurl><stembedurl>https://stocktwits.com/jamstah/message/595671321</stembedurl>Revance, known for its anti-wrinkle injections, has faced a challenging year, with shares down 56.5% so far this year.For updates and corrections email newsroom[at]stocktwits[dot]com.

Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes

The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

RVNC
Revance Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RVNC News

RVNCRevance Therapeutics Inc